Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.
According to IQVIA, US sales of Micafungin for Injection, 50mg and 100mg were approximately $132 million in the 12 months ending August 2021.
Micafungin for Injection is indicated for:
- Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older.
- Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older.
- Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation.
Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product, the company said in its press release.